RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Transplantation

• Publication date

  1995-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00007890-199508000-00010PMID 7544036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase

  1994cited by this paper
• Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

  1994cited by this paper
• Elevation of cytosolic calcium is sufficient to induce growth inhibition in a B cell lymphoma

  1993cited by this paper
• Programmed cell death by bcl‐2‐dependent and independent mechanisms in B lymphoma cells.

  1993cited by this paper
• Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase.

  1993cited by this paper
• p70s6k function is essential for G1 progression

  1993cited by this paper
• Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.

  1993cited by this paper
• REVERSAL OF ONGOING HEART, KIDNEY, AND PANCREAS ALLOGRAFT REJECTION AND SUPPRESSION OF ACCELERATED HEART ALLOGRAFT REJECTION IN THE RAT BY RAPAMYCIN

  1993cited by this paper
• Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle

  1993cited by this paper
• Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases.

  1992cited by this paper
• Synergistic effect of rapamycin and cyclosporine in pancreaticoduodenal transplantation in the rat.

  1992cited by this paper
• The effect of rapamycin on orthotopic small bowel transplantation in the rat.

  1992cited by this paper
• Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin.

  1992cited by this paper
• Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.

  1992cited by this paper
• Activation of p70s6k is associated with phosphorylation of four clustered sites displaying Ser/Thr-Pro motifs.

  1992cited by this paper
• Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.

  1992cited by this paper
• Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

  1992cited by this paper
• Transforming growth factor beta 1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest

  1991cited by this paper
• Cyclosporin A blocks surface IgM‐mediated growth inhibition in an immature B lymphoma, BKS‐2

  1991cited by this paper
• Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A

  1991cited by this paper
• The immunosuppressive effect of rapamycin on pancreaticoduodenal transplants in the rat.

  1991cited by this paper
• Chemistry and biology of the immunophilins and their immunosuppressive ligands.

  1991cited by this paper
• Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes.

  1991cited by this paper
• Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.

  1991cited by this paper
• FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes.

  1991cited by this paper
• The influence of avidity on signaling murine B lymphocytes with monoclonal anti-IgM antibodies. Effects of B cell proliferation versus growth inhibition (tolerance) of an immature B cell lymphoma.

  1991cited by this paper
• Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation.

  1990cited by this paper
• cdc2 gene expression at the G1 to S transition in human T lymphocytes.

  1990cited by this paper
• The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.

  1990cited by this paper
• Probing immunosuppressant action with a nonnatural immunophilin ligand

  1990cited by this paper
• Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.

  1990cited by this paper
• Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase.

  1990cited by this paper
• A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

  1989cited by this paper
• Isolation and immunological characterization of a group of new B lymphomas from CBA mice.

  1989cited by this paper
• bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

  1989cited by this paper
• The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.

  1989cited by this paper
• PRESENSITIZATION AND THE RENAL ALLOGRAFT RECIPIENT

  1989cited by this paper
• A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase

  1989cited by this paper
• Rapamycin for immunosuppression in organ allografting.

  1989cited by this paper
• Studies on FK506 in experimental organ transplantation.

  1988cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Cancers following cyclosporine therapy.

  1987cited by this paper
• Accelerated development of spontaneous thymic lymphomas in male AKR mice receiving cyclosporine.

  1986cited by this paper
• ENHANCEMENT OF THE INDUCTION OF MURINE THYMIC LYMPHOMAS BY CYCLOSPORINE1

  1986cited by this paper
• Monoclonal antibodies specific for murine IgM. II. Activation of B lymphocytes by monoclonal antibodies specific for the four constant domains of IgM

  1985cited by this paper
• Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements.

  1984cited by this paper
• A unique series of lymphomas related to the Ly-1+ lineage of B lymphocyte differentiation.

  1984cited by this paper
• Activity of rapamycin (AY-22,989) against transplanted tumors.

  1984cited by this paper
• Transformation-associated proteins in murine B-cell lymphomas that are distinct from Abelson virus gene products.

  1984cited by this paper
• Cellular mechanisms of immunologic tolerance.

  1983cited by this paper
• Lymphoma in renal allograft patients treated with cyclosporin-A as one of the immunosuppressive agents.

  1981cited by this paper
• Gene required in G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast

  1981cited by this paper
• Inhibition of the immune response by rapamycin, a new antifungal antibiotic.

  1977cited by this paper
• Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

  1975cited by this paper

• Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells

  2024cites this paper
• The immunosuppression effects of deforolimus (ridaforolimus, AP23573) on allograft organ transplantation

  2023cites this paper
• mTOR-regulated mitochondrial metabolism limits mycobacterium-induced cytotoxicity

  2022cites this paper
• Transplant Onconephrology in Patients With Kidney Transplants.

  2022cites this paper
• Naringenin loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in hepatic fibrosis

  2020cites this paper
• Resveratrol and Puerarin loaded polymeric nanoparticles to enhance the chemotherapeutic efficacy in spinal cord injury

  2020cites this paper
• Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms

  2020cites this paper
• Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein‐Barr virus B cell lymphomas and promotes allograft survival

  2019cites this paper
• The role of AMPK/mTOR modulators in therapy of acute myeloid leukemia.

  2018cites this paper
• Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network

  2017cites this paper
• Kinetics studies of the degradation of sirolimus in solid state and in liquid medium

  2017cites this paper
• Cancer After Kidney Transplantation

  2017cites this paper
• Dictyostelium discoideum: A Model System to Study Autophagy Mediated Life Extension

  2017cites this paper
• Targeting Oncoproteins for Molecular Cancer Therapy

  2016cites this paper
• Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation

  2016cites this paper
• Optimal coating method for a dual-layer stent with sirolimus and alpha-lipoic acid in a porcine coronary restenosis model

  2016cites this paper
• Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives

  2016cites this paper
• Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation

  2016cites this paper
• Safety of mTOR inhibitors in adult solid organ transplantation

  2016cites this paper
• Micelle-assisted combination therapies for effective glioblastoma treatment: an in-vitro assessment.

  2015cites this paper
• Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.

  2015cites this paper
• Chapter 92 – Special Considerations for Immunosuppression in Children

  2015cites this paper
• A novel coating of type IV collagen and hyaluronic acid on stent material-titanium for promoting smooth muscle cell contractile phenotype.

  2014cites this paper
• dexamethasone Rapamycin sensitizes multiple myeloma cells to apoptosis induced by

  2013cites this paper
• reduced expression of cyclin D3, cyclin E, cyclin A and survivin Rapamycin induced G1 arrest in cycling B-CLL cells is associated with

  2013cites this paper
• Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins.

  2013cites this paper
• Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

  2013cites this paper
• Immunology/Transplantation.

  2013cites this paper
• Autophagy and the (Pro)renin Receptor

  2013cites this paper
• Rhabdomyosarcoma Cells Induces p53-independent Apoptosis in Human Rapamycin Causes Poorly Reversible Inhibition of mTOR and

  2013cites this paper
• Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin.

  2013cites this paper
• Recent advances in drug eluting stents.

  2013cites this paper
• Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus

  2012cites this paper
• Effect of Immunosuppressive Agents on Long-Term Survival of Renal Transplant Recipients

  2012cites this paper
• Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143

  2012cites this paper
• The Regulation of Mammalian Target of Rapamycin

  2012cites this paper
• Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

  2012cites this paper
• La Rapamycine inhibe l’expression de l’ARNm de l’ADAMTS-4 induit par les cytokines dans les chondrocytes articulaires

  2012cites this paper
• The mTOR Signalling Pathway in Human Cancer

  2012cites this paper
• The Target of Rapamycin: Structure and Functions

  2012cites this paper
• Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells.

  2012cites this paper
• Rapamycin induces p 53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells

  2012cites this paper
• Everolimus Associated with Activated Vitamin D for Post-Transplant Increase Epstein-Barr-Virus Load Treatment. Two Case Reports

  2012cites this paper
• Characterization of the Interaction of Alpha4 Phosphoprotein with Novel Binding Partners: EDD E3 Ubiquitin Ligase and Poly(A)-Binding Protein

  2011cites this paper
• Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

  2011cites this paper
• Sirolimus in pediatric renal transplantation

  2011cites this paper
• Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy.

  2011cites this paper
• Sirolimus addition to tacrolimus‐based immunosuppression induces complete remission of post‐transplant lymphoproliferative disorder in a liver transplant recipient

  2010cites this paper
• Translation deregulation in B-cell lymphomas.

  2010cites this paper
• mTOR signaling in cancer cell motility and tumor metastasis.

  2010cites this paper
• Updates of mTOR inhibitors.

  2010cites this paper
• Rapamycin in combination with donor-specific CD4+CD25+Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation.

  2010cites this paper
• The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells

  2010cites this paper
• The complexes of mammalian target of rapamycin.

  2010cites this paper
• [Regulation of translation initiation].

  2009cites this paper
• Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?

  2009cites this paper
• Rapamycin reduces high-amplitude, mechanical stretch-induced apoptosis in pulmonary microvascular endothelial cells.

  2009cites this paper
• Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.

  2009cites this paper
• Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

  2008cites this paper
• Observation of efficacy and safety of converting the calcineurin inhibitor to sirolimus in renal transplant recipients with chronic allograft nephropathy.

  2008cites this paper
• Calcineurin inhibitors and rapamycin: cancer protection or promotion?

  2007cites this paper
• Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.

  2007cites this paper
• Translation Initiation Factor 4 E Binding Protein 1 , 2 ( 4 EBP 1 , 2 ) in Hematopoiesis And Stress Erythropoiesis

  2007cites this paper
• Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model.

  2007cites this paper
• Laryngeal Transplantation: Research, Clinical Experience, and Future Goals

  2007cites this paper
• Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.

  2007cites this paper
• In Vivo and In Vitro Effect of Sirolimus on Insulin Secretion

  2007cites this paper
• Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation.

  2007cites this paper
• RAD inhibition of sarcoma growth: implications for laryngeal transplantation.

  2007cites this paper
• Mechanisms of sensitization to apoptosis in multiple myeloma.

  2007cites this paper
• Effets des immunosuppresseurs non stéroïdiens sur l'insulinosécrétion en transplantation

  2007cites this paper
• Translation Initiation Factor 4E Binding Protein 1,2 (4E-BP1,2) in Hematopoiesis And Stress Erythropoiesis

  2007cites this paper
• Autres traitements ciblés (trastuzumab exclu)

  2007cites this paper
• Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation Effets des immunosuppresseurs non stéroïdiens sur l’insulinosécrétion en transplantation

  2007cites this paper
• Sirolimus-induced remission of posttransplantation lymphoproliferative disorder.

  2006cites this paper
• Les nouvelles cibles thérapeutiques. Les nouvelles thérapeutiques ciblées

  2006cites this paper
• Diffuse Large B-Cell Lymphoma with Overexpression of Cyclin E Substantiates Poor Standard Treatment Response and Inferior Outcome

  2006cites this paper
• Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

  2006cites this paper
• Everolimus (RAD) Inhibits In Vivo Growth of Murine Squamous Cell Carcinoma (SCC VII)

  2006cites this paper
• Investigating mammalian target of rapamycin inhibitors for their anticancer properties

  2006cites this paper
• Rapamycin Induces a Caspase‐Independent Cell Death in Human Monocytes

  2006cites this paper
• Cell cycle inhibition in malignant lymphoma: disease control by attacking the cellular proliferation machinery.

  2006cites this paper
• Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk

  2006cites this paper
• Central nervous system lymphoproliferative disorder in pediatric kidney transplant recipients

  2006cites this paper
• Immunosuppression in pediatric solid organ transplantation: Opportunities, risks, and management

  2006cites this paper
• Rapamycin Does Not Induce Anergy but Inhibits Expansion and Differentiation of Alloreactive Human T Cells

  2006cites this paper
• Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.

  2005cites this paper
• Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option

  2005cites this paper
• Novel Approaches to the Management of Non-Hodgkin Lymphoma

  2005cites this paper
• Proliferation signal inhibitors: chemical, biologic, and clinical properties

  2005cites this paper
• Inhibitors of the mammalian target of rapamycin

  2005cites this paper
• New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy.

  2005cites this paper
• Sirolimus for solid organ transplantation in children

  2005cites this paper
• The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients

  2005cites this paper
• Induction and Maintenance of Immunosuppression

  2005cites this paper
• The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.

  2005cites this paper
• The mTOR Pathway and Its Inhibitors

  2005cites this paper
• Rapamycin and tumor growth: mechanisms behind its anticancer activity

  2005cites this paper
• mTOR as a target for cancer therapy.

  2004cites this paper
• Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas.

  2004cites this paper